Invivoscribe NPM1 MRD Assay
Just launched! NPM1 MRD Assay* by Invivoscribe.
28May
09May
Biocartis Idylla™ GeneFusion Assay*
THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.
Within 180 minutes and with less than 2 minutes hands-on time, the fully automated Idylla™ GeneFusion cartridge detects ALK, ROS1, RET, NTRK1/2/3 rearrangements and MET exon 14 skipping in a single cartridge using only 1-3* FFPE tissue sections.
14Apr
Devyser thalassemia NGS
THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.
Reduce turnaround time and simplify laboratory workflow with a rapid full-spectrum sequencing single-assay thalassemia DNA screening solution that eliminates multiple parallel test protocols.
12Apr
Biocartis – Clinical utility of Idylla EGFR
THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.
Within 150 minutes and with less than 2 minutes hands-on time, the fully automated Idylla™ EGFR Mutation Test covers 51 mutations in exons 18–21 in a single cartridge
21Mar
Maximise your blood separation!
THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.
Premium blood separator with motor-driven plates, touch screen and integrated bar code scanner.
21Mar
New Invivoscribe FLT3 ITD MRD Assay
THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.
Just launched! Invivoscribe’s FLT3 ITD MRD Assay for Acute Myeloid Leukemia (AML)
21Mar
Are you using Asuragen’s AmplideX FMR1 kit?
THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.
How is your lab performing FMR1 gene testing?
21Mar
Idylla™ EGFR Study Shows Reduction of Time-to-Treatment by 48% for Lung Cancer Patients
THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.
A recent publication of a large prospective study1 demonstrates the Idylla™ EGFR Mutation Test leads to
21Mar
Advantages of Using LymphoTrack Assays
THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.
Invivoscribe LymphoTrack® products can be used for next-generation sequencing (NGS) determination and minimal residual disease (MRD) tracking of B- and T-cell gene rearrangements in subjects suspected of lymphoproliferations.